The University of Texas MD Anderson Cancer Center today was awarded 16 grants totaling over $25.5 million from the Cancer Prevention and Research Institute of Texas (CPRIT) in support of cancer screening, early detection and prevention programs, faculty recruitment, and groundbreaking cancer research across all areas of the institution.
Texas
United-states
John-paul-shen
Neeraj-saini
Scott-kopetz
Daniel-frigo
Richard-bouchard
Guojun-li
Dhussein-abbas
Joseph-ludwig
Jia-wu
Dihua-yu
Brain metastases are among the most severe complications of systemic breast cancer, and overexpression of the human epidermal growth factor receptor 2 (HER2) in breast cancer cells increases the incidence of brain metastases in patients. In this study, we engineered the human-derived, tumor cell tropic neural stem cells LM-NSC008 (LM008) to continuously secrete antibodies against HER2. These anti-HER2 antibodies impaired tumor cell proliferation by inhibiting the PI3K-Akt signaling pathway in HER2+ breast cancer cells in vitro. Importantly, our results demonstrate that the therapeutic combinatorial regimen consisting of LM-NSC008 anti-HER2 antibody-secreting cells and the HER2 kinase inhibitor tucatinib provide therapeutic benefit and prolong survival in preclinical models of HER2+ breast cancer brain metastases.
Houston
Texas
United-states
Boston
Massachusetts
Harvard-university
American
Glo-promega
Trastuzumab-herceptin
Yu-han
Tucatinib-tukysa
Dihua-yu